Rabanal-Ruiz Y, Llanos-Gonzlez E, Alcain FJ
While ZeroHarm claims its manufacturing process, including "aqueous extraction" and "seed-to-supplement", ensures safety, consumer feedback has included "adverse side effects" and "quality control failures"
This typically includes periodic liver function tests, assessment of metabolic parameters, and evaluation of cardiovascular risk factors
This includes cellular health markers, inflammatory markers, metabolic panels, and other relevant biomarkers to ensure safety and track therapeutic response
Two facts about these injections matter more than anything on the marketing page: They are compounded, not manufactured under an FDA-approved drug application
Using a 1:100 ratio of mg tissue to L KME buffer (20 mM MOPS, 120 mM KCl, and 1 mM EGTA, pH 7.4), tissue was homogenized in 2 s bursts separated by a 2 s rest for a total of 10 s (or 3 cycles) at 16,600 rpm using IKA T25 digital Ultra-Turrax homogenizer